Połączenie różnych leków jest konieczne do skorygowania wielu patomechanizmów cukrzycy typu 2
HbA1c: Hemoglobina glikowana
Inhibitor DPP-4: Inhibitor dipeptydylopeptydazy 4
REFERENCJE
1. DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care. 2013; 36(2): 127–138.
2. Schwartz SS, Epstein S, Corkey BE, Grant SFA, Gavin III JR, Aguilar RB. The time is right for a new classification system for diabetes: rationale and implications of the β–cell-centric classification schema. Diabetes Care. 2016; 39: 179–186.
3. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007; 9(2):194–205.
PL-NON-00215
